Skip to Main Content
Contribute Try STAT+ Today

A novel approach to treating Alzheimer’s disease failed to preserve memory and function in a clinical trial, according to results disclosed Tuesday, but a promising signal in a subgroup of patients has the drug’s inventors optimistic about its future.

The treatment, called atuzaginstat, targets the bacteria responsible for gingivitis, which, according to years of compelling research, appears to play a role in the onset and advance of Alzheimer’s. But in a clinical trial involving about 650 patients with mild or moderate Alzheimer’s, the treatment missed its primary endpoint, proving no better than placebo at slowing patients’ decline as measured by tests of cognition and ability to complete basic activities.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment